Table of Contents Author Guidelines Submit a Manuscript
International Journal of Pediatrics
Volume 2012, Article ID 646780, 8 pages
http://dx.doi.org/10.1155/2012/646780
Review Article

Managing the Morbidity Associated with Respiratory Viral Infections in Children with Congenital Heart Disease

1Division of Pediatric Hospital Medicine, Penn State College of Medicine, 500 University Drive, P.O. Box 850, Hershey, PA 17033, USA
2Division of Pediatric Cardiology, Penn State College of Medicine, Hershey, PA 17033, USA

Received 1 August 2011; Accepted 24 December 2011

Academic Editor: Randall Fisher

Copyright © 2012 Joseph M. Geskey and Stephen E. Cyran. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. R. Thiagarajan and P. C. Laussen, “Mortality as an outcome measure following cardiac surgery for congenital heart disease in the current era,” Paediatric Anaesthesia, vol. 21, no. 5, pp. 604–608, 2011. View at Publisher · View at Google Scholar · View at PubMed
  2. G. D. Webb, “Care of adults with congenital heart disease—a challenge for the new millennium,” Thoracic and Cardiovascular Surgeon, vol. 49, no. 1, pp. 30–34, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. O. Loup, C. von Weissenfluh, B. Gahl, M. Schwerzmann, T. Carrel, and A. Kadner, “Quality of life of grown-up congenital heart disease patients after congenital cardiac surgery,” European Journal of Cardio-Thoracic Surgery, vol. 36, no. 1, pp. 105–111, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. F. Eskedal, P. S. Hagemo, A. Eskild, K. F. Frøslie, S. Seiler, and E. Thaulow, “A population-based study relevant to seasonal variations in causes of death in children undergoing surgery for congenital cardiac malformations,” Cardiology in the Young, vol. 17, no. 4, pp. 423–431, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. M. López, L. García-Guereta, and CIVIC Study Group, “Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era,” Pediatric Infectious Disease Journal, vol. 29, no. 12, pp. 1077–1082, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. K. N. Carroll, T. Gebretsadik, M. R. Griffin et al., “Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan,” Pediatrics, vol. 122, no. 1, pp. 58–64, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. C. G. Garcia, R. Bhore, A. Soriano-Fallas et al., “Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis,” Pediatrics, vol. 126, no. 6, pp. e1453–e1460, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. B. Hall, “Respiratory syncytial virus and parainfluenza virus,” The New England Journal of Medicine, vol. 344, no. 25, pp. 1917–1928, 2001. View at Google Scholar
  9. T. F. Feltes, A. K. Cabalka, H. C. Meissner et al., “Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease,” Journal of Pediatrics, vol. 143, no. 4, pp. 532–540, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Meberg and A.-L. Bruu, “Respiratory syncytial virus infections in congenital heart defects—hospitalizations and costs,” Acta Paediatrica, vol. 95, no. 4, pp. 404–406, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. K. Thorburn, “Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection,” Archives of Disease in Childhood, vol. 94, no. 2, pp. 99–103, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. H. Nair, D. J. Nokes, B. D. Gessner et al., “Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis,” The Lancet, vol. 375, no. 9725, pp. 1545–1555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ralston and R. Hill, “Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review,” Journal of Pediatrics, vol. 155, no. 5, pp. 728–733, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. K. Cabalka, “Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease,” Pediatric Infectious Disease Journal, vol. 23, no. 1, supplement, pp. S41–S45, 2004. View at Google Scholar · View at Scopus
  15. N. E. MacDonald, C. B. Hall, and S. C. Suffin, “Respiratory syncytial viral infection in infants with congenital heart disease,” The New England Journal of Medicine, vol. 307, no. 7, pp. 397–400, 1982. View at Google Scholar · View at Scopus
  16. F. W. Moler, A. S. Khan, J. N. Meliones, J. R. Custer, J. Palmisano, and T. C. Shope, “Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience,” Critical Care Medicine, vol. 20, no. 10, pp. 1406–1413, 1992. View at Google Scholar · View at Scopus
  17. A. Khongphatthanayothin, P. Wong, Y. Samara et al., “Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome,” Critical Care Medicine, vol. 27, no. 9, pp. 1974–1981, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. C. A. Altman, J. A. Englund, G. Demmler et al., “Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening,” Pediatric Cardiology, vol. 21, no. 5, pp. 433–438, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. K. Kristensen, L. G. Stensballe, J. Bjerre et al., “Risk factors for respiratory syncytial virus hospitalisation in children with heart disease,” Archives of Disease in Childhood, vol. 94, no. 10, pp. 785–789, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Fabbiani, C. Terrosi, B. Martorelli et al., “Epidemiological and clinical study of viral respiratory tract infections in children from Italy,” Journal of Medical Virology, vol. 81, no. 4, pp. 750–756, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. Miron, I. Srugo, Z. Kra-Oz et al., “Sole pathogen in acute bronchiolitis: is there a role for other organisms apart from respiratory syncytial virus?” Pediatric Infectious Disease Journal, vol. 29, no. 1, pp. e7–e10, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. C. Calvo, F. Pozo, M. L. García-García et al., “Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study,” Acta Paediatrica, vol. 99, no. 6, pp. 883–887, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. N. G. Papadopoulos, M. Moustaki, M. Tsolia et al., “Association of rhinovirus infection with increased disease severity in acute bronchiolitis,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 9, pp. 1285–1289, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. G. Semple, A. Cowell, W. Dove et al., “Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis,” Journal of Infectious Diseases, vol. 191, no. 3, pp. 382–386, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. F. Midulla, C. Scagnolari, E. Bonci et al., “Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants,” Archives of Disease in Childhood, vol. 95, no. 1, pp. 35–41, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. N. Richard, F. Komurian-Pradel, E. Javouhey et al., “The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis,” Pediatric Infectious Disease Journal, vol. 27, no. 3, pp. 213–217, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. O. Wishaupt, A. Russcher, L. C. Smeets, F. G. A. Versteegh, and N. G. Hartwig, “Clinical impact of RT-PCR for pediatric acute respiratory infections: a controlled clinical trial,” Pediatrics, vol. 128, no. 5, pp. e1113–e1120, 2011. View at Publisher · View at Google Scholar · View at PubMed
  28. C. B. Hall, G. A. Weinberg, M. K. Iwane et al., “The Burden of respiratory syncytial virus infection in young children,” The New England Journal of Medicine, vol. 360, no. 6, pp. 588–598, 2009. View at Google Scholar · View at Scopus
  29. D. F. Willson, L. Landrigan, S. D. Horn, and R. J. Smout, “Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia,” Journal of Pediatrics, vol. 143, no. 5, supplement, pp. S142–S149, 2003. View at Google Scholar
  30. S. Esposito, P. Salice, S. Bosis et al., “Altered cardiac rhytm in infants with bronchiolitis and respiratory syncytial virus infection,” BMC Infectious Diseases, vol. 10, article 305, 2010. View at Publisher · View at Google Scholar · View at PubMed
  31. K. Thorburn, M. Eisenhut, A. Shauq, S. Narayanswamy, and M. Burgess, “Right ventricular function in children with severe respiratory syncytial virus (RSV) bronchiolitis,” Minerva Anestesiologica, vol. 77, no. 1, pp. 46–53, 2011. View at Google Scholar
  32. L. Bialy, M. Foisy, M. Smith, and R. M. Fernandes, “The cochrane library and the treatment of bronchiolitis in children: an overview of reviews,” Evidence-Based Child Health, vol. 6, pp. 258–275, 2011. View at Google Scholar
  33. D. Levin, M. Tribuzio, T. Green-Wrzesinki et al., “Empiric antibiotics are justified for infants with respiratory syncytial virus lower respiratory tract infection presenting with respiratory failure: a prospective study and evidence review,” Pediatric Critical Care Medicine, vol. 11, no. 3, pp. 390–395, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. C. McKiernan, L. C. Chua, P. F. Visintainer, and H. Allen, “High flow nasal cannulae therapy in infants with bronchiolitis,” Journal of Pediatrics, vol. 156, no. 4, pp. 634–638, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. S. Johnson, C. Oliver, G. A. Prince et al., “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus,” Journal of Infectious Diseases, vol. 176, no. 5, pp. 1215–1224, 1997. View at Google Scholar · View at Scopus
  36. E. A. F. Simoes, H. M. Sondheimer, F. H. Top et al., “Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease infants and children with congenital heart disease,” Journal of Pediatrics, vol. 133, no. 4, pp. 492–499, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. S. A. Cohen, R. Zanni, A. Cohen, M. Harrington, P. Vanveldhuisen, and M. L. Boron, “Palivizumab use in subjects with congenital heart disease,” Pediatric Cardiology, vol. 29, no. 2, pp. 382–387, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R.-K. R. Chang and A. Y. Chen, “Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease,” Pediatric Cardiology, vol. 31, no. 1, pp. 90–95, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. T. Saji, M. Nakazawa, and K. Harada, “Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease,” Pediatrics International, vol. 47, no. 4, pp. 397–403, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. T. Saji, M. Nakazawa, and K. Harada, “Nationwide survey of palivizumab for respiratory syncytial virus prevention in japanese children with congenital heart disease,” Pediatric Infectious Disease Journal, vol. 27, no. 12, pp. 1108–1109, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. American Academy of Pediatrics, Committee on Infectious Diseases, “Policy statement—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections,” Pediatrics, vol. 124, no. 6, pp. 1694–1701, 2009. View at Publisher · View at Google Scholar · View at PubMed
  42. J. M. Geskey, G. D. Ceneviva, G. Brummel, G. R. Graff, and M. C. Javier, “Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?” Clinical Therapeutics, vol. 26, no. 12, pp. 2130–2137, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. P. Frogel, D. L. Stewart, M. Hoopes, A. W. Fernandes, and P. J. Mahadevia, “A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis,” Journal of Managed Care Pharmacy, vol. 16, no. 1, pp. 46–58, 2010. View at Google Scholar · View at Scopus
  44. H. Wu, D. S. Pfarr, S. Johnson et al., “Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract,” Journal of Molecular Biology, vol. 368, no. 3, pp. 652–665, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. T. F. Feltes, H. M. Sondheimer, R. M. R. Tulloh et al., “A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease,” Pediatric Research, vol. 70, no. 2, pp. 186–191, 2011. View at Publisher · View at Google Scholar · View at PubMed
  46. Q. Zhu, J. M. McAuliffe, N. K. Patel et al., “Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab,” Journal of Infectious Diseases, vol. 203, no. 5, pp. 674–682, 2011. View at Publisher · View at Google Scholar · View at PubMed
  47. J. M. Geskey, N. J. Thomas, and G. L. Brummel, “Palivizumab in congenital heart disease: should international guidelines be revised?” Expert Opinion on Biological Therapy, vol. 7, no. 11, pp. 1615–1620, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. A. Duppenthaler, R. A. Ammann, M. Gorgievski-Hrisoho, J. P. Pfammatter, and C. Aebi, “Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease,” Archives of Disease in Childhood, vol. 89, no. 10, pp. 961–965, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. D. Y. Tam, A. Banerji, B. A. Paes, C. Hui, J. E. Tarride, and K. L. Lanctôt, “The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic,” Journal of Medical Economics, vol. 12, no. 4, pp. 361–370, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. C. Hampp, T. L. Kauf, A. S. Saidi, and A. G. Winterstein, “Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications,” Archives of Pediatrics and Adolescent Medicine, vol. 165, no. 6, pp. 498–505, 2011. View at Publisher · View at Google Scholar · View at PubMed
  51. B. Resch, W. Gusenleitner, M. J. C. Nuijten, M. Lebmeier, and W. Wittenberg, “Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria,” Clinical Therapeutics, vol. 30, no. 4, pp. 749–760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. R. M. R. Tulloh and T. F. Feltes, “The European forum for clinical management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease,” Cardiology in the Young, vol. 15, no. 3, pp. 274–278, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. T. M. Berger, C. Aebi, A. Duppenthaler, and M. Stocker, “Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005),” Infection, vol. 37, no. 2, pp. 109–116, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. R. T. Stein, D. Sherrill, W. J. Morgan et al., “Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years,” The Lancet, vol. 354, no. 9178, pp. 541–545, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Korppi, E. Piippo-Savolainen, K. Korhonen, and S. Remes, “Respiratory morbidity 20 years after RSV infection in infancy,” Pediatric Pulmonology, vol. 38, no. 2, pp. 155–160, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. L. A. Rosenthal, P. C. Avila, P. W. Heymann et al., “Viral respiratory tract infections and asthma: the course ahead,” Journal of Allergy and Clinical Immunology, vol. 125, no. 6, pp. 1212–1217, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. E. A. F. Simoes, X. Carbonell-Estrany, C. H. L. Rieger, I. Mitchell, L. Fredrick, and J. R. Groothuis, “The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children,” Journal of Allergy and Clinical Immunology, vol. 126, no. 2, pp. 256–262, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. B. S. Graham, “Biological challenges and technological opportunities for respiratory syncytial virus vaccine development,” Immunological Reviews, vol. 239, no. 1, pp. 149–166, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. J. Chin, R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette, “Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population,” American Journal of Epidemiology, vol. 89, no. 4, pp. 449–463, 1969. View at Google Scholar · View at Scopus
  60. V. A. Fulginiti, J. J. Eller, O. F. Sieber, J. W. Joyner, M. Minamitani, and G. Meiklejohn, “Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent paratnfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine,” American Journal of Epidemiology, vol. 89, no. 4, pp. 435–448, 1969. View at Google Scholar · View at Scopus
  61. S. D. Little-van den Hurk, J. W. Mapletoft, N. Arsic, and J. Kovacs-Nolan, “Immunopathology of RSV infection: prospects for developing vaccines without this complication,” Reviews in Medical Virology, vol. 17, no. 1, pp. 5–34, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. H. Nair, V. R. Verma, E. Theodoratou et al., “An evaluation of the emerging interventions against respiratory syncytial virus (RSV)-associated acute lower respiratory infections in children,” BMC Public Health, vol. 11, article S30, 2011. View at Publisher · View at Google Scholar · View at PubMed
  63. J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson et al., “A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 19, pp. 8800–8805, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus